Robinson B A, Clutterbuck R D, Millar J L, McElwain T J
Br J Cancer. 1985 Nov;52(5):733-7. doi: 10.1038/bjc.1985.251.
The effect of epidermal growth factor (hEGF) on intestinal epithelial damage by melphalan was explored in CBA mice. Human EGF was administered in doses of 100 micrograms kg-1 or 1000 micrograms kg-1 using a variety of schedules. Mucosal damage was assessed 4, 8 and 13 days later, by [14C]-xylose uptake and by microcolony survival of jejunum, ileum and colon. The only regimen to show enhanced jejunal crypt survival was administration of hEGF, 100 micrograms kg-1, i.p., 8 hourly, beginning 24 h before melphalan treatment. Oral administration of hEGF had no effect on melphalan induced damage nor on subsequent recovery of intestinal mucosa. Activity of hEGF in mice was confirmed by demonstration of precocious eyelid opening in newborn mice. No consistent protective or restorative effect of hEGF on melphalan-induced intestinal epithelial damage could be demonstrated with the doses and schedules used.
在CBA小鼠中研究了表皮生长因子（hEGF）对美法仑所致肠道上皮损伤的影响。采用多种给药方案，以100微克/千克或1000微克/千克的剂量给予人表皮生长因子。在4天、8天和13天后，通过[14C] -木糖摄取以及空肠、回肠和结肠的微集落存活情况评估黏膜损伤。唯一显示空肠隐窝存活率提高的方案是在美法仑治疗前24小时开始，以100微克/千克的剂量腹腔注射hEGF，每8小时一次。口服hEGF对美法仑诱导的损伤以及随后肠黏膜的恢复均无影响。通过证明新生小鼠眼睑过早张开，证实了hEGF在小鼠体内的活性。在所使用的剂量和给药方案下，未发现hEGF对美法仑诱导的肠道上皮损伤有一致的保护或修复作用。
